Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

OGSIVEO

NIROGACESTAT HYDROBROMIDE

Standard Dose
EQ 50MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview OGSIVEO is listed in Drugs@FDA under application 217677 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient NIROGACESTAT HYDROBROMIDE Form and strength TABLET;ORAL - EQ 50MG BASE Sponsor SPRINGWORKS Submission history Latest submission status date: 2026-03-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview OGSIVEO is listed in Drugs@FDA under application 217677 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NIROGACESTAT HYDROBROMIDE Form and strength TABLET;ORAL - EQ 50MG BASE Sponsor SPRINGWORKS Submission history Latest submission status date: 2026-03-10 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.